ApoGlyx
New therapeutic concepts for sepsis
- CEO: Michael Rützler
- First investment year: 2021
- Fund: South
- Business sector: Life Science
ApoGlyx
ApoGlyx develops new therapeutic concepts for metabolical and inflammatory diseases, such as sepsis, with innovative and proprietary Aquaporin technology.